PDCD1 and plasma cell myeloma: Lenalidomide maintenance treatment also reduced programmed cell death protein 1 (PD-1) expression on CD8+ T cells, suggesting that it has the potential to counter-act the myeloma induced exhaustion or senescence on T cells (36).